bexotegrast
bexotegrast: developed by 1 company · 3 clinical trials tracked.
bexotegrast evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could bexotegrast → PLRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) Idiopathic Pulmonary Fibrosis; Primary Sclerosing Cholangiti… | Phase 2 |
Clinical Trials (3)
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
Primary endpoint: Change From Baseline in Forced Vital Capacity at Week 52
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Primary endpoint: Primary Outcome
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events
Frequently asked questions
Who is developing bexotegrast?
bexotegrast is being developed by PLIANT THERAPEUTICS, INC..
How many clinical trials involve bexotegrast?
BioSniper tracks 3 clinical trials involving bexotegrast.